The New York Times reports that medical device manufacturer Johnson & Johnson continued to market artificial hip implants abroad after the FDA prohibited the sale of these devices in the United States.
In August 2010, Johnson & Johnson subsidiary DePuy® Orthopaedics issued a voluntary recall of its ASR™ XL Acetabular Hip Replacement System and ASR™ Hip Resurfacing System following thousands of reports to the FDA from patients alleging device failure. The company continues to sell a similar model, the DePuy Pinnacle® Modular Hip Replacement System, despite similar adverse reports from patients.
Although the exact number of people who received a DePuy hip implant overseas is unknown, the recalled implants were placed in an estimated 93,000 people worldwide during the eight years the products were on the market. One-third of those 93,000 were in the United States.
Read the full article about recalled hip implants being marketing overseas featured in The New York Times.
Motley Rice member and medical device lawyer Don Migliori serves on the Plaintiffs' Steering Committee for both the DePuy ASR XL® and DePuy Pinnacle multidistrict litigation, representing people who have suffered serious injury or required a revision surgery following implantation with one of these hip implant devices.
Learn more about DePuy hip implants and how Motley Rice attorneys fight for people suffering because of potentially defective devices and fight to hold accountable those responsible for negligent medical care, corporate wrongdoing and inadequate research and product development.